Core Viewpoint - The article discusses the recent performance of the A-share market, highlighting a recovery in the Shanghai Composite Index after a political bureau meeting that released positive signals for the economy and investment opportunities in the innovative pharmaceutical sector [1][2][8]. Group 1: A-share Market Performance - The A-share market experienced a pullback but rebounded in the afternoon, with the Shanghai Composite Index closing in the green, reaching a new high for the year [2][7]. - The market showed significant structural differentiation, with consumer and banking sectors rising while technology and new energy sectors faced declines [6][7]. - The trading volume exceeded 1.84 trillion yuan, indicating active market participation [5]. Group 2: Political Bureau Meeting Insights - The Central Political Bureau meeting emphasized the need to "stably resolve local government debt risks" and introduced a roadmap for "clearing financing platforms," alleviating systemic risk concerns [9]. - The meeting also highlighted the importance of stimulating domestic demand and implementing actions to boost consumption, positively impacting sectors like tourism, retail, and food and beverage [10]. - A focus on technological innovation was reiterated, aiming to foster new competitive industries and integrate technological advancements with industrial development [12]. Group 3: Investment Opportunities in Innovative Pharmaceuticals - A significant number of funds have achieved over 100% returns this year, particularly in the innovative pharmaceutical sector, with several funds listed showing substantial year-to-date performance [17]. - Fund managers suggest a cautious yet optimistic approach to the innovative pharmaceutical sector, advising investors to match risk and return expectations and avoid excessive chasing of high-flying stocks [18][19]. - Key guidelines for selecting funds include focusing on long-term performance stability, understanding investment strategies, and aligning with personal risk preferences [20].

Core Viewpoint - The announcement from Huatai Fund Management Co., Ltd. indicates the suspension of large-scale subscription and regular investment business for the Huatai Hong Kong Advantage Selected Mixed Securities Investment Fund starting from July 23, 2025, to protect the interests of fund shareholders and ensure stable fund operations [1][2] Fund Suspension Details - The Huatai Hong Kong Advantage Selected Mixed (QDII) A and C funds will both suspend large-scale subscriptions and regular investment business, with a limit of 2 million RMB per day for each fund account [1][2] - Any single or cumulative subscription or regular investment exceeding 2 million RMB will be partially or fully rejected by the company [1][2] - Other business operations for the funds will continue as usual during the suspension period, and the specific time for resuming large-scale subscriptions and investments will be announced later [1][2]